Philadelphia, PA, April 8, 2013 Although mammography, the gold standard of breast cancer screening, reduces breast cancer mortality, it has important limitations. Critics point to reduced sensitivity for women with dense breasts, a high rate of false positives leading to excessive biopsies, and concerns about long-term effects of repeated radiation. With greater understanding of risk stratification, the authors of this review envision a re-thinking of the typical breast cancer paradigm to include new technologies that allow a more individualized approach that integrates patient-specific metrics, such as age, breast density, and personal preference. The review is published in the June issue of The American Journal of Medicine.
The authors discuss the pros and cons of new technologies for breast cancer screening. For instance, "digital breast tomosynthesis is an imaging technique aimed at eliminating the pitfalls of overlapping breast tissue. It has the potential to lower recall rates on screening mammography and reduce false negative examinations due to dense breast tissue," says lead author Jennifer S. Drukteinis, MD, of the H. Lee Moffitt Cancer Center and Research Institute in Tampa. MRI, which offers improved sensitivity but reduced specificity, is appropriate for high-risk patients. Other technologies outlined are contrast-enhanced mammography, low-dose mammography, automated whole breast ultrasound, and positron emission mammography.
"Given the heterogeneity of the human population, a 'perfect' imaging technology for breast cancer screening will likely never be found. In fact, because of this heterogeneity, the very concept of 'one strategy fits all' may be outmoded," says Dr. Drukteinis.
"The development of a personalized, individual patient-centered approach to breast cancer screening mirrors the evolution of similar strategies in other aspects of medicine," writes Robert G. Stern, MD, a radiologist affiliated with th
|Contact: Jane Grochowski|
Elsevier Health Sciences